Sort
51,593 grants matching “hepatitis”
ECONOMIC COST OF DRUG USE AND ABUSE
$686,729Rosalie Pacula · Rand Corporation · R01 · FY2009 · DA
Antiretroviral Therapy and the Hepatitis C Virus
$686,648Kenneth E Sherman · University Of Cincinnati · R01 · FY2008 · AI
Obesity Brain Expression
$686,624Anita L Destefano · Boston University Medical Campus · R01 · FY2014 · DK
Optimizing PrEP regimens for pregnant women in sub-Saharan Africa
$686,617Benjamin H Chi · Univ Of North Carolina Chapel Hill · R01 · FY2021 · AI
Determinants of Coronavirus Fidelity in Replication and Pathogenesis
$686,584Mark R Denison · Vanderbilt University Medical Center · R01 · FY2018 · AI
Development of a novel drug candidate that inhibits hepatitis B virus covalently
$686,525Haitao Guo · Indiana University Indianapolis · R01 · FY2015 · AI
Disparities in the Diffusion of Direct-Acting Antiviral Therapy for Hepatitis C among Baby Boomers: A Mixed-Methods Study
$686,519Martin F Shapiro · Weill Medical Coll Of Cornell Univ · R01 · FY2021 · DK
Clinical & Immunological Study of Treatment Withdrawal in E-Ag Negative Hepatitis B
$686,488Stewart Cooper · California Pacific Med Ctr Res Institute · R01 · FY2024 · DK
Warfarin Pharmacogenetics in Pediatric Patients
$686,402Ronald N Hines · Medical College Of Wisconsin · R01 · FY2010 · HD
Strengthening the Evidence-Base for Drug-Disease Interactions in Older Adults
$686,333Tobias Gerhard · Rutgers, The State Univ Of N.J. · R01 · FY2019 · AG
Control of Autoimmunity by Regulatory T Cells
$686,264Ethan Shevach · National Institute Of Allergy And Infectious Diseases · ZIA · FY2015 · AI
Cholesterol toxicity in alcohol-associated hepatitis
$686,264Zhenghui Gordon Jiang · Beth Israel Deaconess Medical Center · R01 · FY2024 · AA
Biomarkers for Peripheral Circadian Clocks in Humans
$686,135Kenneth P Wright · University Of Colorado · R01 · FY2025 · HL
Sickle Cell Disease and Sickle Cell Trait Protection Against HIV-1-infection in Africans and African Americans
$686,095Sergei Nekhai · Howard University · R01 · FY2022 · HL
3/4 Alcohol Research Consortium in HIV - Epidemiological Research Arm (ARCH-ERA)
$686,094Heidi M. Crane · University Of Washington · U01 · FY2018 · AA
Quantitation of Factors Regulating Glucose Tolerance
$686,062Richard N. Bergman · University Of Southern California · R01 · FY2010 · DK
Non-Human Primate Core (NHP Core)
$686,024Koen K Van Rompay · Duke University · P01 · FY2016 · AI
Clinical Resource for Alcoholic Hepatitis Inestigation
$685,927Zhaoli Sun · Johns Hopkins University · R24 · FY2025 · AA
Clinical Resource for Alcoholic Hepatitis Inestigation
$685,927Zhaoli Sun · Johns Hopkins University · R24 · FY2024 · AA
Clinical Resource for Alcoholic Hepatitis Inestigation
$685,927Zhaoli Sun · Johns Hopkins University · R24 · FY2023 · AA
Applying a Human Liver Microphysiology System to Develop Therapeutic Strategies for Non-Alcoholic Fatty Liver Disease (NAFLD)
$685,914D. Lansing Taylor · University Of Pittsburgh At Pittsburgh · R01 · FY2019 · DK
The Progression of Hepatitis C Among IDUs
$685,883David L Thomas · Johns Hopkins University · R01 · FY2006 · DA
Vitamin E Pharmacokinetics And Biomarkers In Normal And Obese Women
$685,846Mark A Levine · National Institute Of Diabetes And Digestive And Kidney Diseases · ZIA · FY2020 · DK
Development and Validation of a Novel and HIV-Relevant Prediction Model for Fracture
$685,782Evelyn Hsieh · Yale University · R01 · FY2023 · AR
HIV, HCV and the Menopausal Transition: Effects on Steatosis and Fibrosis Progression
$685,752Phyllis C Tien · Northern California Institute/Res/Edu · R01 · FY2019 · DK